All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2023-04-17

More than 1 million lives saved in Europe by COVID-19 vaccines since the end of 2020: research presented at European Congress of Clinical Microbiology & Infectious Diseases

COVID-19 vaccination directly saved at least 1,004,927 lives across Europe between December 2020 and March 2023, according to new research being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April). The new estimates by WHO/Europe and presented at the conference by Dr Margaux Meslé,  Epidemiologist at

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-04-13

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

A nonstatin therapy approved almost 3 years ago to treat low-density lipoprotein (LDL) cholesterol also cuts the risk of major cardiovascular events, especially heart attacks, according to data presented. Bempedoic acid, approved in February 2020 as Nexletol (Esperion), reduced by 13% the risk of a 4-part composite end point of major adverse cardiovascular events (MACE),

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2023-04-13

New therapy harnesses patients’ blood cells to fight tumors

Noninvasive approach is fast, cost-effective and could be used to treat a variety of cancers doptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2023-04-13

Severe Covid-19: new anti-C5a antibody approved by FDA

A new antibody drug by pharmaceutical company inflaRx received FDA emergency use authorization to treat critically ill Covid-19 patients. One of the greatest hurdles for monoclonal antibody development during the Covid-19 pandemic is the ongoing mutation of the SARS-CoV-2 virus. Most antibodies introduced throughout the pandemic targeted the virus spike protein, which mutates significantly with every emerging

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-03-30

Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia can avoid amputation

A study published in the New England Journal of Medicine has shown that there may finally be an alternative to amputation for patients suffering from chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. This study, co-led by University Hospitals (UH) Harrington Heart & Vascular Institute, could lead to the first FDA approval of

Read More

One comment InRESEARCH
PIER MARIA FORNASARI
2023-03-14

Attracting Stem Cells and Facilitating Bone Regeneration by Adhesive Protein

A joint research team of POSTECH, Kyungpook National University, and Korea University Anam Hospital developed an osteogenic barrier coating material that maximizes the effect of guided bone regeneration (GBR) for implant placements. One of the key factors of success in a dental implant is the condition of the periodontium around the implant. A higher long-term

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2023-03-01

Researchers of MGH Bioengineer an Endocrine Pancreas for Type 1 Diabetes

Key Takeaways In people with type 1 diabetes, the body’s immune system attacks and destroys insulin-producing β cells that control blood glucose levels and are part of a group of cells in the pancreas called pancreatic islets. In research published in Cell Reports Medicine, a team led by investigators at Massachusetts General Hospital (MGH), a founding member

Read More

No Comments InREGENERATIVE MEDICINE